These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8093908)

  • 41. Effect of the new antiallergic drug epinastine on chemical mediator induced bronchoconstrictions in guinea pigs.
    Misawa M; Kanai Y
    Arzneimittelforschung; 1991 Nov; 41(11):1145-9. PubMed ID: 1725697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
    Modesti PA; Colella A; Cecioni I; Costoli A; Biagini D; Migliorini A; Neri Serneri GG
    Am Heart J; 1995 May; 129(5):873-9. PubMed ID: 7732975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
    Mallarkey G; Smith GM
    Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes.
    Hung SC; Ghali NI; Venton DL; Le Breton GC
    Biochim Biophys Acta; 1983 Feb; 728(2):171-8. PubMed ID: 6219702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets.
    Hedberg A; Hall SE; Ogletree ML; Harris DN; Liu EC
    J Pharmacol Exp Ther; 1988 Jun; 245(3):786-92. PubMed ID: 2968449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
    Halushka PV; Mais DE; Saussy DL
    Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of thromboxane A2/prostaglandin H2 receptor in the vasoconstrictor response of rat aorta to endothelin.
    Reynolds EE; Mok LL
    J Pharmacol Exp Ther; 1990 Mar; 252(3):915-21. PubMed ID: 2138670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conformationally restricted analogs of histamine H1 receptor antagonists. Trans- and cis-1,5-Diphenyl-3-dimethylaminopyrrolidine.
    Hanna PE; Ahmed AE
    J Med Chem; 1973 Sep; 16(9):963-8. PubMed ID: 4147659
    [No Abstract]   [Full Text] [Related]  

  • 51. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential histamine H2-receptor autagonists. 1. Aminoethylimidayo(1,2-a)pyridines and -imidayo(1,5-a)pyridines.
    Durant GJ; Loynes JM; Wright HB
    J Med Chem; 1973 Nov; 16(11):1272-6. PubMed ID: 4147837
    [No Abstract]   [Full Text] [Related]  

  • 53. Glomerular thromboxane A2/prostaglandin H2 receptors: characterization and effect of adriamycin-induced nephrotic syndrome.
    Mayeux PR; Shah SV
    Biochim Biophys Acta; 1993 Apr; 1181(2):148-54. PubMed ID: 8481403
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.
    Brittain RT; Boutal L; Carter MC; Coleman RA; Collington EW; Geisow HP; Hallett P; Hornby EJ; Humphrey PP; Jack D
    Circulation; 1985 Dec; 72(6):1208-18. PubMed ID: 2998642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 9,11-epoxy-9-homoprosta-5-enoic acid analogues as thromboxane A2 receptor antagonists.
    Das J; Hall SE; Nakane M; Haslanger MF; Reid JA; Garber D; Truc VC; Harris DN; Hedberg A; Ogletree ML
    J Med Chem; 1990 Jun; 33(6):1741-8. PubMed ID: 2140414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resting myocardial ischemia after intravenous infusion of BM 13.177 (sulotroban), a thromboxane receptor antagonist.
    Terres W; Kupper W; Hamm CW; Bleifeld W
    Thromb Res; 1987 Dec; 48(5):577-83. PubMed ID: 2964739
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacology of thromboxane A2 receptor antagonists.
    Halushka PV
    Z Kardiol; 1989; 78 Suppl 3():42-7. PubMed ID: 2530712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and evaluation of novel thiazolidine derivatives as thromboxane A2 receptor antagonists.
    Sato M; Kawashima Y; Goto J; Yamane Y; Chiba Y; Jinno S; Satake M; Imanishi T; Iwata C
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):521-9. PubMed ID: 8004696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of thromboxane receptors in human platelets.
    Jones RL; Wilson NH; Armstrong RA
    Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.